ER PR ~ 81. Estrogen Receptor ER 50 ± D5 1A6 CB11 STOVT3D1 EliVision 1. 3.

Μέγεθος: px

Εμφάνιση ξεκινά από τη σελίδα:

Download "ER PR ~ 81. Estrogen Receptor ER 50 ± D5 1A6 CB11 STOVT3D1 EliVision 1. 3."

Μυρρίνη Αντωνόπουλος
5 χρόνια πριν
Προβολές:

1 680 Joural of Nigxia Medical Uiversity TOPOⅡ ER PR C - erbb DNA Ⅱ TOPOⅡ ER PR c - erbb - 2 Elivisio 166 ER PR C - erbb - 2 DNA TOPOⅡ 166 ER PR c - erbb - 2 DNA TOPOⅡ 72. 9% 121 / % 105 / % 83 / % 74 / 166 c - erbb - 2 TOPOⅡ P < ER PR 50 < 50 c - erbb - 2 > 2cm 2cm P < ER PR c - erbb - 2 TOPOⅡ P < TOPOⅡ ER PR P < C - erbb - 2 TOPOⅡ P < c - erb - B2 TOPOⅡ C - erbb - 2 TOPOⅡ R A Estroge Receptor ER Progesteroe Receptor PR 50 ± ~ 81 ER PR c - erbb - 2 4% > 5cm 20 1 DNA 1. 2 ER PR C - erbb - 2 TOPOⅡ Ⅱ topoimeraseⅡ TOPOⅡ DNA 1D5 1A6 CB11 STOVT3D1 EliVisio 1. 3 Eliviso ER PR C - erbb - 2 4μm TOPOⅡ H 2 O 2 10mi PBS 3 10mi 4 EliVisio 60mi DAB PBS NZ E - mail xxyy@hotmail. com 1. 4 ER PR C - erbb TOPOⅡ C - erbb - 2 TOPOⅡ

2 7. TOPOⅡ ER PR C - erbb ER PR 10% + < < ER PR 50 10% ER PR 1. 5 SPSS c - erbb - 2 TOPOⅡ χ 2 Pearso % ER PR c - erbb - 2 TOPOⅡ ER PR c - erbb P TOPOⅡ ER PR < 50 χ 2 = P < P > c - erbb - 2 P > c - erbb - 2 TOPOⅡ > 2cm P < ER PR c - erbb - 2 TOPOⅡ 2cm χ 2 = P < c - erbb - 2 ER PR c - erbb - 2 P > TOPOⅡ TOPOⅡ P > χ 2 = χ = P 2 2 ER PR c - erbb - 2 TopoⅡ ER PR C - erbb - 2 TopoⅡ / / / / % % % % / < / cm > < 50 2cm P < ER PR c - erbb - 2 TOPO Ⅱ TOPOⅡ ER PR TOPO TOPOⅡ + - /% χ2 P Ⅱ ER PR χ 2 = χ 2 ER = P < ER TOPOⅡ ER PR PR γ = γ = C - erbb - 2 PR TOPOⅡ c - erbb C - erbb - 2 χ 2 = c - erbb EP PR ER PR 3 ER PR c - erbb - 2 P < r = ER PR ER PR

3 C - erbb C - erbb ER PR TOPOⅡ ER PR 5 C - erbb - 2 TOPOⅡ 4 Topo Ⅱ α C - erbb - 2 HER - 2 /eu CerbB kDa 5 ER PR C - erbb - 2 TOPOⅡ C - erbb - 2 c - erb - B2 TOPO C - erbb - 2 Ⅱ ER PR C - erbb - 2 TOPOⅡ C - erbb Slamo DJ Leylad Joes B Shak S et a1. Use of chemotherapy plus a moocloal atibody agaist HER2 for metastatic breast cacer that over expresses HER2 C - erbb J. Egl Med C - 2 Ma Y Lespagard L Durbecq V et al. Polysomy17 i erbb - 2 Her - 2 /eu status elaboratio i breast cacer effect o daily practice J. Cli Cacer Res TOPOⅡ α β 3 Caldarella A. Female breast cacer status accordig to DNA DNA ER PR ad HER2 expressio a populatio based a- Topo Ⅱ α alysis J. Pathol Ocol Res q21. 3CerbB q TopoⅡα 4. J Vamesu Sl. Agiogeesis ad c - erbb - 2 HER2 / S G 2 TopoⅡα eu overexpressio status i primary breast cacer patiets a aalysis of 158 eedle core biopsies J. G 1 G 0 10 TOPOⅡ Rom Morphol Embryol TOPOⅡ 6 Kaptai S Tam LK Che B. HER - 2 /eu ad breast P < cacer J. Diag Mol Pathol TOPOⅡ 7 Sharifah NA. C - erbb - 2 oco - protei expressio i breast cacer relatioship to tumour characteristics ad TOPOⅡ short - term survival i Uiversiti Kebasaa Malaysia Medical Cetre J. Asia Pac Cacer Prev TOPOⅡ 8 Cordoba O. Complete pathological remissio i a patiet DNA with hormoe - receptor positive ad c - erbb - 2 expressio - egative breast cacer treated with FAC TOPOⅡ TOPOⅡ chemotherapy durig pregacy J. Tumori C - erbb - 2 TOPOⅡ 9 Pritchard KI Shepherd LE. HER2 ad resposiveess 12 of breast cacer to adjuvat chemotherapy J. N Egl J Med

4 7. TOPOⅡ ER PR C - erbb Yabuki N. Immuohistochemical study of DNA topoisomerase II i huma gastric disorders J. Am J Pathol Tokiiwa H. Topoisomerase II alpha expressio ad the Ki - 67 labelig idex correlate with progostic factors i estroge receptor - positive ad huma epidermal growth factor type egative breast cacer J. Breast Cacer Taer B. Expressio of c - erbb - 2 ad topoisomerase II alpha i relatio to chemoresistace i ovaria cacer J. Zetralbl Gyakol Campiglio M Somezi G Olgiati C et al. Role of proliferatio i HER2 status predicted respose to doxorubici J. It J Ocol Expressio ad Sigificace of ER PR C - erbb - 2 ad TOPOⅡ i Breast Cacer RONG Xiao - wei ZHAO Xue - ya ZHU Meg XU Yua - yi Nigxia Medical Uiversity Yichua Abstract Objective To observe the expressio ad sigificace of ER PR C - erbb - 2 ad DNA topoisomerase Ⅱ TOPOⅡ i breast cacer. Methods 166 specimes of breast cacer were icluded. The expressios of ER PR C - erbb - 2 ad TOPOⅡi breast cacer were detected by usig immuohistochemical method. The relatioship betwee the cliicopathological factors was observed. Results I 166 specimes of breast cacer the positive expressio rate of ER PR C - erbb - 2 ad TOPOⅡwas 72. 9% 121 / % 105 / % 83 /166 ad 44. 6% 74 /166 respectively. The positive expressio rates of C - erbb - 2 ad TOPOⅡ i the cacer tissue sigificatly icreased compared with i adjacet ormal breast tissue P < the ER ad PR positive expressio rates of breast cacer patiets aged 50 years or above were sigificatly higher tha those of patiets aged below 50 years the positive expressio rate of c - erbb - 2 i breast cacer patiets with tumor size > 2cm was sigificatly higher tha that of patiets with tumor size 2cm P < ER PR c - erbb - 2 ad TOPO II - positive expressio i breast cacer with lymph ode metastasis were sigificatly higher tha those without lymph ode metastasis P < TOPOⅡad ER PR showed sigificatly egative correlatio P < C - erbb - 2 ad TOPOⅡhad sigificatly positive correlatio P < Coclusio c - erb - B2 ad TOPOⅡ has relatioship with lymphatic metastasis of beast cacer. Key words breast cacer C - erbb - 2 TOPOⅡ GB x 珋 M 2 s 3 s r 4 t t 5 F F 6 χ 2 7 r 8 v 9 P P t χ 2 q t χ 2

Σχετικά έγγραφα

IL - 13 /IL - 18 ELISA PCR RT - PCR. IL - 13 IL - 18 mrna. 13 IL - 18 mrna IL - 13 /IL Th1 /Th2

IL - 13 /IL - 18 ELISA PCR RT - PCR. IL - 13 IL - 18 mrna. 13 IL - 18 mrna IL - 13 /IL Th1 /Th2 344 IL - 13 /IL - 18 1 2 1 2 1 2 1 2 1 2 3 1 2 13 18 IL - 13 /IL - 18 10% / OVA /AL OH 3 5% 16 ~ 43 d 44 d ELISA BALF IL - 13 IL - 18 PCR RT - PCR IL - 13 IL - 18 mrna IL - 13 mrna 0. 01 IL - 18 mrna 0.